In the first article, by using ChIP assay, the authors show that p65 subunit of NF-κB following TRAIL treatment binds to the Mcl-1 promoter, which suggested that TRAIL induced expression of Mcl-1 through activation of NF-κB in HCT-116 colon carcinoma cells [ 17].
Notably, of all p53 DNA binding sites about 45% (for Actinomycin D treatment) and 37% (for Etoposide treatment) are bound by phosphorylated p53 (Figure S3).
Thus, there are numerous target sites that upon Etoposide treatment are bound by p53 that is phosphorylated at S46 to a higher extent than upon Actinomycin D treatment.
But if the diagnosis is wrong in the first place, treatment is bound to be misguided.
Selecting the right treatment is bound to be challenging and confusing because the scientific data behind most menopausal remedies remain sketchy.
In response to insulin treatment, USF bound to the E-box recruits SREBP-1c to the nearby SREs.
Briefly, α-lactalbumin was partially unfolded by EDTA treatment and bound to oleic acid by ion exchange chromatography on a DEAE-Trisacryl M column (Pall BioSepra, Cergy-Saint-Christophe, France) preconditioned with oleic acid.
The link seems very indirect and RA treatment is bound to have many effects that are independent of the changes in Gli3.
In MCF-7 cells, following paclitaxel treatment, Bmf bound Bcl-2 but not Bcl-xL or Mcl-1, and Bim was displaced from Bcl-2, but not Bcl-xL or Mcl-1.
When fluorescent EV particles of strain IHD-J mCherry A5 F13–GFP were subjected to the same treatment and bound to cover slips, however, no significant loss of F13 GFP fluorescence was detected (data not shown), suggesting that disrupted EV membranes remained associated with the underlying virus particle.
